Yale and Transcend wins US DoD grant for PTSD therapy

22 Sep 2023
www.pharmaceutical-technology.com
Phase 2Fast Track
Yale and Transcend wins US DoD grant for PTSD therapy
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Yale and Transcend wins US DoD grant for PTSD therapy
Preview
Source: Pharmaceutical Technology
Methylone (TSND-201) is a rapid-acting neuroplastogen (a biological substrate not a therapeutic). Image Credit: MargJohnsonVA / Shutterstock.
The US Department of Defense has awarded a collaborative grant to Transcend Therapeutics and Yale University (US).
The grant is to fund the preclinical research of Transcend’s lead candidate, methylone for treating post-traumatic stress disorder (PTSD). The funding builds on Yale University’s $1m Department of Defense (DoD) grant to study the mechanism of action of methylone and midomafetamine (MDMA) in PTSD.
Recommended Reports
Yale and Transcend wins US DoD grant for PTSD therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Histamine Dihydrochloride in Chronic Traumatic Encephalopathy (CTE) GlobalData
Yale and Transcend wins US DoD grant for PTSD therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Bavisant Dihydrochloride in Hypersomnia GlobalData
View allCompanies IntelligenceBionomics LtdYale UniversityDodTranscend Therapeutics IncView all
Methylone (TSND-201) is a rapid-acting neuroplastogen (a biological substrate not a therapeutic).
Transcend is conducting a placebo-controlled Phase I/II trial (NCT05741710) in the UK to evaluate the safety and efficacy of methylone in treating patients with severe PTSD.
Part A of the study was an open-label study and was expected to enrol up to 15 participants with PTSD. Top-line data from this part is expected by the end of this year. Part B of the trial will be a randomised, double-blind, placebo-controlled study enrolling up to 64 patients.
Transcend’s co-founder and medical adviser for the US Department of Veterans Affairs National Center for PTSD stated: “There is a tremendous demand, especially among veterans, for new and effective treatments for PTSD.”
Multiple PTSD treatments currently in development include Halucenex’s synthetic psilocybin, which showed a 40% reduction in PTSD symptoms in the Phase II trial. Bionomics is expected to announce the Phase IIb trial (NCT04951076) results for BNC210 in Q3 2023. BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor and has received a fast track designation from the Food and Drug Administration (FDA) for treating PTSD.
The US DoD has also sponsored a PTSD Phase II trial (NCT05422612) for the combination therapy of Idorsia Pharmaceuticals’ Quviviq (daridorexant), fluoxetine and vilazodone hydrochloride.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.